Adjunctive Bright Light Therapy for Bipolar Depression: a Randomized Double-Blind Placebo-Controlled Trial
ARTICLES Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial Dorothy K. Sit, M.D., James McGowan, B.A., Christopher Wiltrout, B.S., Rasim Somer Diler, M.D., John (Jesse) Dills, M.L.S., James Luther, M.A., Amy Yang, M.S., Jody D. Ciolino, Ph.D., Howard Seltman, M.D., Ph.D., Stephen R. Wisniewski, Ph.D., Michael Terman, Ph.D., Katherine L. Wisner, M.D., M.S. Objective: Patients with bipolar disorder have recurrent major Pittsburgh Sleep Quality Index. Remission was defined as depression, residual mood symptoms, and limited treatment having a SIGH-ADS score of 8 or less. options. Building on promising pilot data, the authors conducted a6-weekrandomizeddouble-blindplacebo-controlledtrialto Results: At baseline, both groups had moderate depression investigate the efficacy of adjunctive bright light therapy at and no hypomanic or manic symptoms. Compared with the midday for bipolar depression. The aims were to determine placebo light group, the group treated with bright white light remission rate, depression symptom level, and rate of mood experienced a significantly higher remission rate (68.2% com- polarity switch, as well as to explore sleep quality. pared with 22.2%; adjusted odds ratio=12.6) at weeks 4–6and significantly lower depression scores (9.2 [SD=6.6] compared Method: The study enrolled depressed adults with bipolar I or with14.9[SD=9.2]; adjusted b=–5.91) at the endpoint visit. No II disorder who were receiving stable dosages of antimanic mood polarity switches were observed. Sleep quality improved medication (excluding patients with hypomania or mania, mixed in both groups and did not differ significantly between them.
[Show full text]